Vir Biotechnology

Agenovir Corporation is dedicated to the research and development of antiviral therapeutics aimed at addressing diseases linked to latent or persistent viral reservoirs. Founded in 2014 and headquartered in South San Francisco, California, the company specializes in innovative nucleases, including CRISPR/Cas9 technology, to disrupt viral DNA. This approach enables the development of a new class of therapeutics designed to eliminate pathogenic viral genomes, thereby providing healthcare providers with effective treatment options for patients suffering from chronic viral infections. Agenovir operates as a subsidiary of Vir Biotechnology, Inc. as of January 31, 2019.

Humabs BioMed SA is a biopharmaceutical company based in Bellinzona, Switzerland, specializing in the development of human monoclonal antibody platforms aimed at treating infectious and inflammatory diseases. Founded in 2004, the company collaborates with pharmaceutical firms and academic institutions to advance its innovative therapies. Humabs has two clinical-stage partnered programs, including a notable collaboration with MedImmune, AstraZeneca's biologics research and development arm, focusing on an antibody against the influenza A virus, which has shown efficacy against all known subtypes. This project has successfully completed clinical phase 1b/2a trials and has been documented in prestigious scientific journals. Additionally, Humabs is working with Novartis on an antibody targeting an undisclosed indication, which is currently in phase 2 of clinical development. The company's monoclonal antibodies are designed to harness the human immune system's natural responses, thereby providing new therapeutic options for serious infections and addressing unmet medical needs in the treatment of rare diseases.

TomegaVax Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies aimed at addressing significant medical needs. The company's focus is on the preclinical and clinical advancement of vaccines and immunotherapies targeting chronic and recurring viral infections, including Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Hepatitis B Virus (HBV), and Herpes Simplex Virus (HSV). TomegaVax's unique platform offers continuous low-level antigen presentation, which helps maintain an active T-cell-mediated immune response, thereby enabling more effective immune-based therapies for difficult-to-treat viral infections. Through its pioneering approach, TomegaVax aims to improve patient outcomes in the field of infectious diseases.